readthroughSign in
CompanyINTSNasdaqShelton, CT

Intensity Therapeutics, Inc.

Late-stage clinical biotechnology company developing INT230-6, an engineered cytotoxic formulation administered by intratumoral injection for solid tumors including sarcomas and breast cancer.

8-KNov 5Latest SEC filing
Nov 3Latest story

November 2026

August 2026